[Administration of exogenous surfactant in premature very low birth weight infants with RDS]

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Critical Care Medicine

Background:

• Respiratory distress syndrome (RDS) is a significant cause of morbidity and mortality in very low birth weight infants (VLBWI).
• Surfactant replacement therapy is a cornerstone in managing RDS, but comparisons between different surfactant preparations are crucial.

Purpose of the Study:

• To evaluate the impact of surfactant therapy on pulmonary function, survival, and complications in VLBWI with RDS.
• To compare the efficacy of Curosurf and Exosurf versus no surfactant treatment.

Main Methods:

• A retrospective study involving 67 VLBWI (<1500g) with RDS.
• Infants were divided into three groups: Curosurf treatment (n=27), Exosurf treatment (n=16), and control (no surfactant, n=24).
• Data collected included mechanical ventilation duration, oxygen therapy, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), and mortality.

Main Results:

• Infants treated with Curosurf demonstrated the shortest duration of mechanical ventilation and oxygen therapy.
• The Curosurf group exhibited a lower incidence of BPD, IVH, and mortality compared to the Exosurf and control groups.
• Despite a lower gestational age and higher incidence of inborn infection in the Curosurf group, outcomes were still favorable.

Conclusions:

• Curosurf therapy is associated with improved respiratory outcomes and reduced complications in VLBWI with RDS.
• Surfactant therapy, particularly with Curosurf, significantly benefits premature infants suffering from respiratory distress.
• Further research may explore optimal surfactant strategies for this vulnerable population.